Educational analysis only — not financial advice. Always do your own due diligence.
AMGN trades against a final fair-value range of $366.98-$644.16, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
A bear caseBear caseThe worst-realistic outcome — what happens if our top three risks materialize together. Used to set the floor of our fair-value range and inform position sizing. scenario assumes a 20% margin compression and 5% annual revenue decline. This resets the fair valueFair valueOur composite estimate of intrinsic per-share value, blended across DCF, exit-multiple, and reverse-DCF methods. Reported as a low/mid/high range to capture model uncertainty. to the $366 level, providing a margin of safetyMargin of safetyThe discount required between fair value and current price before we recommend buying. Typically 15% for wide-moat names, 25–35% for cyclicals or low-confidence cases. near current market prices.
Obesity pipeline asset MariTide fails to meet efficacy or safety endpoints in Phase 2/3, removing the primary growth re-acceleration catalyst.
CMS negotiations result in net price reductions exceeding 40% for top assets Enbrel and Prolia, significantly faster than model decay assumptions.
Synergies from the Horizon acquisition fail to materialize while high interest rates increase the burden of the $54.6B debt load, strangling FCF.
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net income, accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
